Epidermal Growth Factor Receptor Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Epidermal Growth Factor Receptor stocks.

Epidermal Growth Factor Receptor Stocks Recent News

Date Stock Title
Nov 19 BMY Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Nov 19 BMY Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Nov 18 BMY Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Nov 18 BMY Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
Nov 18 BMY EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
Nov 17 BMY Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Nov 17 BMY Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock
Nov 15 BMY Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
Nov 15 BMY Bristol Myers gets positive EMA opinion for repotrectinib
Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Nov 15 CKPT Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)
Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
Nov 14 BMY Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
Nov 14 BMY Tudor Investment adds Infinera, Trane, exits Disney, UnitedHealth, among top Q3 trades
Nov 14 CKPT Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
Nov 14 BMY Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week
Nov 14 BMY 2 Beaten-Down Dividend Stocks to Buy and Hold
Nov 13 BMY Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
Nov 13 BMY Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?
Epidermal Growth Factor Receptor

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.Epidermal growth factor and its receptor was discovered by Stanley Cohen of Vanderbilt University. Cohen shared the 1986 Nobel Prize in Medicine with Rita Levi-Montalcini for their discovery of growth factors.
Deficient signaling of the EGFR and other receptor tyrosine kinases in humans is associated with diseases such as Alzheimer's, while over-expression is associated with the development of a wide variety of tumors. Interruption of EGFR signalling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumours and improve the patient's condition.

Browse All Tags